|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dørum A, Kristensen GB, Abeler VM, Tropé
CG and Møller P: Early detection of familial ovarian cancer. Eur J
Cancer. 32A:1645–1651. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yawn BP, Wollan P, Klee M and Barrette B:
Ovarian carcinoma: care and survival in a community-based
population. Clin Ther. 23:146–159. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Padilla LA, Radosevich DM and Milad MP:
Limitations of the pelvic examination for evaluation of the female
pelvic organs. Int J Gynaecol Obstet. 88:84–88. 2005. View Article : Google Scholar
|
|
5
|
Minaretzis D, Tsionou C, Tziortziotis D,
Michalas S and Aravantinos D: Ovarian tumors: prediction of the
probability of malignancy by using patient’s age and tumor
morphologic features with a logistic model. Gynecol Obstet Invest.
38:140–144. 1994. View Article : Google Scholar
|
|
6
|
Osmers RG, Osmers M, von Maydell B, Wagner
B and Kuhn W: Evaluation of ovarian tumors in post-menopausal women
by transvaginal sonography. Eur J Obstet Gynecol Reprod Biol.
77:81–88. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guerriero S, Ajossa S, Garau N, et al:
Ultrasonography and color Doppler-based triage for adnexal masses
to provide the most appropriate surgical approach. Am J Obstet
Gynecol. 192:401–406. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Szpurek D, Moszyniki R, Zietkowiak W, et
al: An ultrasonographic morphological index for prediction of
ovarian tumor malignancy. Eur Gynaecol Oncol. 26:51–54. 2005.
|
|
9
|
U.S. Preventive Services Task Force.
Screening for ovarian cancer: recommendation statement. Ann Fam
Med. 2:260–262. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fishman DA, Cohen L, Blank SV, et al: The
role of ultrasound evaluation in the detection of early-stage
epithelial ovarian cancer. Am J Obstet Gynecol. 192:1214–1222.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Negus RP, Stamp GW, Hadley J and Balkwill
FR: Quantitative assessment of the leukocyte infiltrate in ovarian
cancer and its relationship to the expression of C-C chemokines. Am
J Pathol. 150:1723–1734. 1997.PubMed/NCBI
|
|
12
|
Mantovani G, Macciò A, Pisano M, et al:
Tumor-associated lympho-monocytes from neoplastic effusions are
immunologically defective in comparison with patient autologous
PBMCs but are capable of releasing high amounts of various
cytokines. Int J Cancer. 71:724–731. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dobrzycka B, Terlikowski SJ, Kowalczuk O
and Kinalski M: Circulating levels of TNF-alpha and its soluble
receptors in the plasma of patients with epithelial ovarian cancer.
Eur Cytokine Netw. 20:131–134. 2009.PubMed/NCBI
|
|
14
|
Charles KA, Kulbe H, Soper R, et al: The
tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in
ovarian cancer in mice and humans. J Clin Invest. 119:3011–3023.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou J, Ye F, Chen H, Lv W and Gan N: The
expression of interleukin-10 in patients with primary ovarian
epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med
Res. 35:290–300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tavares-Murta BM, de Cunha FQ, Miranda R,
Adad SJ and Murta EFC: Differential tumor microenvironment in human
ovarian cystic tumors. Tumori. 90:491–497. 2004.
|
|
17
|
Murta EF, da Silva CS, Gomes RA, et al:
Ultrasonographic criteria and tumor marker assay are good
procedures for the diagnosis of ovarian neoplasia in preselected
outpatients. Eur J Gynaecol Oncol. 25:707–712. 2004.PubMed/NCBI
|
|
18
|
Murta EF and Nomelini RS: Early diagnosis
and predictors of malignancy of adnexal masses. Curr Opin Obstet
Gynecol. 18:14–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
No authors listed. International
Federation of Gynecology and Obstetrics annual report on the
results of treatment in gynecologic cancer. Int J Gynaecol Obstet.
28:189–190. 1993.
|
|
20
|
Szlosarek PW, Grimshaw MJ, Kulbe H, et al:
Expression and regulation of tumor necrosis factor alpha in normal
and malignant ovarian epithelium. Mol Cancer Ther. 5:382–390. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sethi G, Sung B and Aggarwal BB: TNF: a
master switch for inflammation to cancer. Front Biosci.
13:5094–5107. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Balkwill F: Tumor necrosis factor or tumor
promoting factor? Cytokine Growth Factor Rev. 13:135–14. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bertazza L and Mocellin S: Tumor necrosis
factor (TNF) biology and cell death. Front Biosci. 13:2736–2743.
2008. View Article : Google Scholar
|
|
24
|
Anderson GM, Nakada MT and DeWitte M:
Tumor necrosis factor-alpha in the pathogenesis and treatment of
cancer. Curr Opin Pharmacol. 4:314–320. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Szlosarek PW, Grimshaw MJ, Wilbanks GD, et
al: Aberrant regulation of argininosuccinate synthetase by
TNF-alpha in human epithelial ovarian cancer. Int J Cancer.
121:6–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gadducci A, Ferdeghini M, Castellani C, et
al: Serum levels of tumor necrosis factor (TNF), soluble receptors
for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in
epithelial ovarian cancer. Gynecol Oncol. 58:184–188. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Radke J, Schmidt D, Böhme M, et al:
Cytokine level in malignant ascites and peripheral blood of
patients with advanced ovarian carcinoma. Geburtshilfe
Frauenheilkd. 56:83–87. 1996.(in German). View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hassan F, Islam S, Tumurkhuu G, et al:
Involvement of interleukin-1 receptor-associated kinase (IRAK)-M in
toll-like receptor (TLR) 7-mediated tolerance in RAW 264.7
macrophage-like cells. Cell Immunol. 256:99–103. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nowak M, Klink M, Glowacka E, et al:
Production of cytokines during interaction of peripheral blood
mononuclear cells with autologous ovarian cancer cells or benign
ovarian tumour cells. Scand J Immunol. 71:91–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Daraï E, Detchev R, Hugol D and Quang NT:
Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour
necrosis factor-alpha in women with endometriomas and benign and
malignant cystic ovarian tumours. Hum Reprod. 18:1681–685. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kozłowski L, Zakrzewska I, Tokajuk P and
Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6),
interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of
breast cancer patients. Rocz Akad Med Bialymst. 48:82–84. 2003.
|
|
32
|
Rabinovich A, Medina L, Piura B and
Huleihel M: Expression of IL-10 in human normal and cancerous
ovarian tissues and cells. Eur Cytokine Netw. 21:122–128.
2010.PubMed/NCBI
|
|
33
|
Yigit R, Massuger LF, Figdor CG and
Torensma R: Ovarian cancer creates a suppressive microenvironment
to escape immune elimination. Gynecol Oncol. 117:366–72. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao G, Sun J, Gao J, Xiong L, Yu L and Gao
Y: Chronic stress promoted the growth of ovarian carcinoma via
increasing serum levels of norepinephrine and interleukin-10 and
altering nm23 and NDRG1 expression in tumor tissues in nude mice.
Biosci Trends. 7:56–63. 2013.PubMed/NCBI
|
|
35
|
Liu CZ, Zhang L, Chang XH, et al:
Overexpression and immunosuppressive functions of transforming
growth factor 1, vascular endothelial growth factor and
interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res.
24:130–137. 2012. View Article : Google Scholar
|
